the role of pd-l1: is it accurate enough as a biomarker for immunotherapy response?
Published 6 years ago • 412 plays • Length 3:50Download video MP4
Download video MP3
Similar videos
-
2:41
should pd-l1 be used as a biomarker for immunotherapy in bladder cancer?
-
5:27
immunotherapy in oncology and the role of the pd-l1 biomarker
-
3:47
a keynote on pd-l1 as a predictive biomarker of immunotherapy response: a complex picture
-
2:55
blueprint project update: how comparable are the results of different pd-l1 assays?
-
3:43
biomarkers in nsclc: a pathologist's insight into pd-l1 and tmb
-
2:13
the value of pd-l1 as a biomarker beyond lung cancers
-
5:06
should pd-l1 be used as a biomarker for immunotherapy in lung cancer?
-
5:02
going beyond pd-l1 testing for lung cancer immunotherapy
-
1:34
evolving role of pd-l1 as a biomarker
-
0:48
expert discusses the role of pd-l1 expression as a predictive biomarker in urothelial carcinoma
-
1:33:59
revisiting pd-l1 as an immunotherapy biomarker across the cancer spectrum
-
3:13
pd-l1 and alternative biomarkers in head and neck cancer
-
1:41
dr. goldberg on pd-l1 as a biomarker in lung cancer
-
1:24
dr. lilenbaum on pd-l1 as a predictive biomarker for immunotherapy in lung cancer
-
9:54
is the pd-l1 biomarker ready for prime time?
-
6:56
all you need to know about pd-l1 by immunohistochemistry
-
1:14
dr. postow on using pd-l1 as a biomarker of response
-
0:46
immune checkpoint inhibitors: recent progress and potential biomarkers - 3iv pd-l1 overexpression
-
31:50
predictive biomarkers of checkpoint blockades with keith flaherty, md